ValiRx - VAL201 Clinical Trial Update
VAL Wed, 30 Sep 2020, 09:00am BST
Dr Suzy Dilly, Chief Executive Officer provides an update on the headline results from the recently completed Phase 1/2 clinical trial of its lead asset VAL201, for the treatment of advanced prostate cancer, held at University College Hospital, London.
Suzanne Dilly
Chief Executive Officer
Suzanne Dilly, Chief Executive Officer
Thu, 14 Jul 2022, 1:30pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 30 Jun 2022, 11:00am BST
Management Team, ValiRx PLC
Wed, 6 Apr 2022, 5:00pm BST
Suzanne Dilly, Chief Executive Officer
Wed, 23 Mar 2022, 12:56pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 5 Jan 2022, 12:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 20 Dec 2021, 12:20pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 26 Nov 2021, 4:48pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 2 Nov 2021, 5:00pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 28 May 2021, 12:30pm BST
Suzanne Dilly, Chief Executive Officer
Mon, 15 Feb 2021, 12:00pm GMT
Dr Suzanne Dilly and Dr Kevin Cox
Tue, 8 Dec 2020, 2:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 30 Nov 2020, 3:30pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 30 Sep 2020, 9:00am BST
Suzanne Dilly, Chief Executive Officer
Wed, 8 Jul 2020, 3:15pm BST
Dr George Morris, Chief Operating Officer
Wed, 11 Sep 2019, 4:10pm BST
Victoria D'Aquino, Research and Development Officer
Thu, 4 Jul 2019, 9:00am BST
Dr George Morris, Chief Operating Officer
Thu, 20 Jun 2019, 12:20pm BST
Dr George Morris, Chief Operating Officer
Thu, 2 May 2019, 1:16pm BST
